BeiGene マネジメント

マネジメント基準チェック /24

BeiGeneの CEO はJohn Oylerで、 Jan2010年に任命され、の在任期間は 14.83年です。の年間総報酬はCN¥ 134.33Mで、 4.6%給与と95.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の6.9%を直接所有しており、その価値は$ 1.42B 。経営陣と取締役会の平均在任期間はそれぞれ2.5年と4.3年です。

主要情報

John Oyler

最高経営責任者

CN¥134.3m

報酬総額

CEO給与比率	4.6%
CEO在任期間	14.8yrs
CEOの所有権	6.9%
経営陣の平均在職期間	2.5yrs
取締役会の平均在任期間	4.3yrs

経営陣の近況

Recent updates

BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion

Nov 06

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Aug 22

Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

Aug 14

BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

Aug 09

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Jun 21

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

May 30

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

Apr 21

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

Mar 08

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Jan 31

CEO報酬分析

BeiGene の収益と比較して、John Oyler の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-CN¥6b
Jun 30 2024	n/a	n/a	-CN¥4b
Mar 31 2024	n/a	n/a	-CN¥6b
Dec 31 2023	CN¥134m	CN¥6m	-CN¥6b
Sep 30 2023	n/a	n/a	-CN¥7b
Jun 30 2023	n/a	n/a	-CN¥13b
Mar 31 2023	n/a	n/a	-CN¥13b
Dec 31 2022	CN¥124m	CN¥6m	-CN¥14b
Sep 30 2022	n/a	n/a	-CN¥15b
Jun 30 2022	n/a	n/a	-CN¥14b
Mar 31 2022	n/a	n/a	-CN¥12b
Dec 31 2021	CN¥106m	CN¥5m	-CN¥9b
Sep 30 2021	n/a	n/a	-CN¥9b
Jun 30 2021	n/a	n/a	-CN¥9b
Mar 31 2021	n/a	n/a	-CN¥8b
Dec 31 2020	CN¥94m	CN¥5m	-CN¥11b
Sep 30 2020	n/a	n/a	-CN¥10b
Jun 30 2020	n/a	n/a	-CN¥10b
Mar 31 2020	n/a	n/a	-CN¥8b
Dec 31 2019	CN¥88m	CN¥5m	-CN¥7b
Sep 30 2019	n/a	n/a	-CN¥6b
Jun 30 2019	n/a	n/a	-CN¥5b
Mar 31 2019	n/a	n/a	-CN¥5b
Dec 31 2018	CN¥192m	CN¥4m	-CN¥5b
Sep 30 2018	n/a	n/a	-CN¥3b
Jun 30 2018	n/a	n/a	-CN¥2b
Mar 31 2018	n/a	n/a	-CN¥923m
Dec 31 2017	CN¥67m	CN¥3m	-CN¥606m

報酬と市場: Johnの総報酬 ($USD 18.56M ) は、 US市場 ($USD 12.73M ) の同規模の企業の平均を上回っています。

報酬と収益: Johnの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

John Oyler (56 yo)

14.8yrs

在職期間

CN¥134,331,046

報酬

Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
John Oyler	Co-Founder	14.8yrs	CN¥134.33m	6.9% $ 1.4b
Xiaobin Wu	President & COO	6.5yrs	CN¥78.08m	0.056% $ 11.5m
Xiaodong Wang	Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder	14.8yrs	CN¥31.35m	0.83% $ 170.3m
Chan Lee	General Counsel & Senior VP	2.3yrs	CN¥28.74m	0.017% $ 3.5m
Wang Lai	Global Head of R&D	no data	CN¥51.93m	0.13% $ 26.6m
Aaron Rosenberg	CFO & Principal Financial Officer	less than a year	データなし	データなし
Titus Ball	VP & Chief Accounting Officer	less than a year	データなし	0.0033% $ 689.4k
Liza Heapes	Head of Investor Relations	no data	データなし	データなし
Yang Ji	Chief Compliance Officer	1.1yrs	データなし	データなし
Yan Qi	Senior VP & Head of Public Affairs - Greater China	3.8yrs	データなし	データなし
Jason Radford	Senior Vice President of Strategy & Corporate Development	1.8yrs	データなし	データなし
Mark Lanasa	Senior VP & Chief Medical Officer for Solid Tumors	2.8yrs	データなし	データなし

2.5yrs

平均在職期間

53.5yo

平均年齢

経験豊富な経営陣: BGNEの経営陣は経験豊富であると考えられます ( 2.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
John Oyler	Co-Founder	14.1yrs	CN¥134.33m	6.9% $ 1.4b
Xiaodong Wang	Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder	8.8yrs	CN¥31.35m	0.83% $ 170.3m
Steven Young	Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board	3.6yrs	データなし	データなし
Michael Goller	Independent Non-Executive Director & Member of the Scientific Advisory Committee	9.6yrs	CN¥3.42m	0.0034% $ 697.6k
Corazon Sanders	Independent Non-Executive Director & Member of Scientific Advisory Committee	4.3yrs	CN¥3.56m	0.0022% $ 445.8k
Anthony Hooper	Independent Non-Executive Director	4.8yrs	CN¥3.64m	0.0027% $ 559.3k
Shalini Sharp	Director	less than a year	データなし	データなし
Alessandro Riva	Co-Chairman of Scientific Advisory Committee & Independent Non-Executive Director	2.8yrs	CN¥3.49m	0.0021% $ 441.7k
Olivier Brandicourt	Independent Non-Executive Director	less than a year	データなし	0% $ 0
Ranjeev Krishana	Independent Lead Director	10.1yrs	CN¥3.46m	0.0034% $ 697.6k
Margaret Han Dugan	Member of Scientific Advisory Board & Independent Non-Executive Director	2.8yrs	CN¥3.62m	0.0021% $ 441.7k

4.3yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: BGNEの取締役会は経験豊富であると考えられます ( 4.3年の平均在任期間)。

BeiGene マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

BeiGene, Ltd. Announces Passing Away of Donald Glazer, A Board Member and the Chair of the Nominating and Corporate Governance Committee

Co-Founder notifies of intention to sell stock

Global Head of R&D notifies of intention to sell stock

BeiGene, Ltd. Appoints Shalini Sharp to Board of Directors and Member of the Audit Committee, Effective September 27, 2024

President & COO notifies of intention to sell stock

President & COO notifies of intention to sell stock

Recent updates

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion

New minor risk - Shareholder dilution

BeiGene, Ltd. Announces Passing Away of Donald Glazer, A Board Member and the Chair of the Nominating and Corporate Governance Committee

Co-Founder notifies of intention to sell stock

BeiGene, Ltd. to Report Q3, 2024 Results on Nov 13, 2024

Global Head of R&D notifies of intention to sell stock

BeiGene, Ltd. Appoints Shalini Sharp to Board of Directors and Member of the Audit Committee, Effective September 27, 2024

President & COO notifies of intention to sell stock

BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy

President & COO notifies of intention to sell stock

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

Consensus estimates of losses per share improve by 31%

BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BeiGene, Ltd. to Report Q2, 2024 Results on Aug 07, 2024

Beigene, Ltd. Appoints Aaron Rosenberg as the Principal Financial Officer, Effective from July 22, 2024

BeiGene, Ltd. Announces CFO Changes

BeiGene, Ltd. to Report First Half, 2024 Results on Aug 30, 2024

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

First quarter 2024 earnings released: US$2.41 loss per share (vs US$3.35 loss in 1Q 2023)

BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

BeiGene, Ltd., Annual General Meeting, Jun 05, 2024

Co-Founder recently sold US$7.5m worth of stock

Co-Founder notifies of intention to sell stock

BeiGene, Ltd. to Report Q1, 2024 Results on May 11, 2024

BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Co-Founder notifies of intention to sell stock

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

BeiGene, Ltd. Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

BeiGene, Ltd. to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024

BeiGene, Ltd. Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Full year 2023 earnings released: US$8.45 loss per share (vs US$19.43 loss in FY 2022)

BeiGene, Ltd. Announces Adults Living with Chronic Lymphocytic Leukemia in Ontario and Quebec Now Have Access, Through Public Reimbursement, to BRUKINSA® (Zanubrutinib)

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Now 21% undervalued after recent price drop

Beigene, Ltd. Announces Board Changes

Now 22% undervalued after recent price drop

Forecast to breakeven in 2026

BeiGene, Ltd. Announces FDA Approves Label Update for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

BeiGene, Ltd. Receives European Commission Approval for BRUKINSA®? (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Co-Founder notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 11%

Consensus EPS estimates upgraded to US$11.07 loss

Beigene, Ltd. Receives Positive Recommendation from Nice in U.K. for Adult Patients with Chronic Lymphocytic Leukemia

BeiGene, Ltd. Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeli

Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

Consensus EPS estimates fall by 18%

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

U.S. FDA Accepts Biologics License Application in First-Line Advanced ESCC

BeiGene, Ltd. Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA(R)

Beigene, Ltd. Announces Change of Chair of Audit Committee

New minor risk - Profitability

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$3.64 loss per share (vs US$5.51 loss in 2Q 2022)

Beigene Announces Positive CHMP Opinion for Tislelizumab as Treatment for Advanced or Metastatic ESCC

マネジメント基準チェック /24